KFDA intention misinterpreted, say officials

Published: 2004-06-02 06:59:00

Updated: 2004-06-02 06:59:00

Rejecting media reports, the Korea Food and Drug Administration said recently that it did not intend to side with latecomers, such as Daewoong and Yuhan Corp. in the controversial issue involving omission of clinical trials on novel amodipine salts, following the expiration of Pfizer's amlodipine...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK